Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Biofrontera ( (DE:B8FK) ) is now available.
Biofrontera AG and Biofrontera Inc. have successfully met the conditions for a strategic restructuring agreement, which involves a significant reorganization of their collaboration. This agreement includes a transfer of assets related to the US marketing of Ameluz® to Biofrontera Inc., with considerations including preferred shares and ongoing license fees, potentially impacting the company’s market positioning and financial dynamics.
More about Biofrontera
Biofrontera AG operates in the pharmaceutical industry, focusing on the development and commercialization of dermatological products. Its primary product, Ameluz®, is used in photodynamic therapy for skin cancer treatment and is marketed in the US and other regions.
YTD Price Performance: 6.05%
Average Trading Volume: 1,603
Technical Sentiment Signal: Strong Sell
Current Market Cap: €13.86M
For a thorough assessment of B8FK stock, go to TipRanks’ Stock Analysis page.